Extracorporeal Photopheresis in Sezary Syndrome
Plain-language summary
This is a research study collecting clinical information and/or biological samples from patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome whose disease has come back or stopped responding to prior treatment to advance understanding of these diseases and improve future treatments. No experimental treatment is given as part of this study. This trial is available at 3 locations in the United States.
Who can join (key eligibility)
- Age 18 Years to 100 Years years
- Lymphoma came back or did not respond to prior treatment
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Extracorporeal photopheresis (ECP) (DEVICE): Extracorporeal photopheresis is a process that exposes a collection of white blood cells and plasma to a light sensitizing agent, methoxsalen, and returns that compartment to the body. | Methoxsalen Injection (DRUG): Methoxsalen is a light-sensitizing sterile compound added to the collected white blood cells and plasma during ECP.
Extracorporeal photopheresis (ECP), Methoxsalen Injection
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details